SRC and ovarian cancer: This underscores the concept that simultaneous blockade of multiple cell growth/survival pathways, including JAK/STAT3, PI3K/AKT/mTOR, SRC and MEK/MAPK, may be required to achieve maximum anti-tumor activity in patients with ovarian cancer.